[go: up one dir, main page]

MX2022006732A - Conjugados peptidicos y metodos de uso. - Google Patents

Conjugados peptidicos y metodos de uso.

Info

Publication number
MX2022006732A
MX2022006732A MX2022006732A MX2022006732A MX2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A
Authority
MX
Mexico
Prior art keywords
peptide
receptor
modulates
glp
peptide conjugates
Prior art date
Application number
MX2022006732A
Other languages
English (en)
Inventor
Weijun Shen
Elsa Pflimlin
Sam Lear
Zaid Amso
Peter G Schultz
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022006732A publication Critical patent/MX2022006732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan en la presente conjugados peptídicos que comprenden un péptido seleccionado de un péptido que modula el receptor del PYY, un péptido que modula tanto el receptor del GLP-1 como el receptor del GCG, un péptido que modula tanto el receptor del GLP-1 como el receptor del GIP, y un péptido que modula el receptor del GLP-1; y una estructura tipo grapa unida al péptido en un primer aminoácido y en un segundo aminoácido. También se proporcionan conjugados peptídicos que comprenden el péptido liberador de prolactina. Los conjugados peptídicos pueden utilizarse para tratar afecciones tales como la obesidad. Además se proporcionan péptidos liberadores de prolactina engrapados.
MX2022006732A 2019-12-04 2020-12-03 Conjugados peptidicos y metodos de uso. MX2022006732A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943667P 2019-12-04 2019-12-04
US202062994791P 2020-03-25 2020-03-25
PCT/US2020/063149 WO2021113535A1 (en) 2019-12-04 2020-12-03 Peptide conjugates and methods of use

Publications (1)

Publication Number Publication Date
MX2022006732A true MX2022006732A (es) 2022-08-19

Family

ID=76222285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022006732A MX2022006732A (es) 2019-12-04 2020-12-03 Conjugados peptidicos y metodos de uso.
MX2022006861A MX2022006861A (es) 2019-12-04 2020-12-03 Agonistas del receptor glp2 y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006861A MX2022006861A (es) 2019-12-04 2020-12-03 Agonistas del receptor glp2 y metodos de uso.

Country Status (10)

Country Link
US (2) US20230071371A1 (es)
EP (2) EP4069726A4 (es)
JP (2) JP2023504184A (es)
KR (2) KR20220123648A (es)
CN (2) CN115052615A (es)
AU (2) AU2020397918A1 (es)
CA (2) CA3163507A1 (es)
IL (2) IL293522A (es)
MX (2) MX2022006732A (es)
WO (2) WO2021113535A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082797A4 (en) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US20230071371A1 (en) * 2019-12-04 2023-03-09 The Scripps Research Institute Peptide conjugates and methods of use
IL309067A (en) 2021-06-09 2024-02-01 Scripps Research Inst Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN116970063A (zh) * 2022-04-29 2023-10-31 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商Ｄ＆Ｄ製藥科技股份有限公司 用於治療神經病症之組合物及方法
AU2023410450A1 (en) * 2022-12-21 2025-06-19 Boehringer Ingelheim International Gmbh Glp1/gip/npy2 receptor triple agonists
CN117586374B (zh) * 2023-10-07 2024-11-29 深圳湾实验室 Glp-1r/gipr/gcgr三重激动剂类似物及其用途
WO2025184552A2 (en) * 2024-03-01 2025-09-04 The Scripps Research Institute Dual gip/glp-1 peptide conjugates and methods of use
WO2025217640A1 (en) * 2024-04-12 2025-10-16 Eli Lilly And Company Compositions and methods for treating metabolic diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011274474B2 (en) * 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
ES2927607T3 (es) * 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
EP3082797A4 (en) * 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2016205488A1 (en) * 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA3097104A1 (en) * 2018-04-19 2019-10-24 Stichting Vu Protein macrocyclization
US20230071371A1 (en) * 2019-12-04 2023-03-09 The Scripps Research Institute Peptide conjugates and methods of use

Also Published As

Publication number Publication date
IL293522A (en) 2022-08-01
CA3163522A1 (en) 2021-06-10
US20230071371A1 (en) 2023-03-09
CN115052886A (zh) 2022-09-13
JP7691421B2 (ja) 2025-06-11
MX2022006861A (es) 2022-07-11
EP4069726A2 (en) 2022-10-12
IL293460A (en) 2022-07-01
CN115052886B (zh) 2025-09-09
AU2020397917A1 (en) 2022-06-23
EP4069274A1 (en) 2022-10-12
KR20220123648A (ko) 2022-09-08
CA3163507A1 (en) 2021-06-10
WO2021113535A1 (en) 2021-06-10
US20230057847A1 (en) 2023-02-23
AU2020397918A1 (en) 2022-06-23
KR20220110244A (ko) 2022-08-05
EP4069274A4 (en) 2024-04-10
CN115052615A (zh) 2022-09-13
EP4069726A4 (en) 2024-03-20
WO2021113524A2 (en) 2021-06-10
JP2023513658A (ja) 2023-04-03
JP2023504184A (ja) 2023-02-01
WO2021113524A3 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2022006732A (es) Conjugados peptidicos y metodos de uso.
CL2020000299A1 (es) Compuestos, composiciones y métodos.
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
CO2018002328A2 (es) Formulaciones que comprenden variantes de péptido natriurético de tipo c (cnp)
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
CO2022004335A2 (es) Variantes del cnp y sus conjugados
CO2021010490A2 (es) Compuestos, composiciones y métodos
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
CO2018009120A2 (es) Genes del factor viii optimizados
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
ECSP10010287A (es) Vectores de virus oncolíticos de viruela
AR093788A1 (es) Inmunoterapia con agentes de enlace
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
EA201592281A1 (ru) Новые модуляторы рецептора glp-1
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
UY37456A (es) Inmunoglobulinas y sus usos
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados